Drug Drug Interaction (DDI)
Conditions
Keywords
DDI, Itraconazole, Fluvoxamine, TD-9855, Smoking, Caffeine, CYP1A2, CYP3A4
Brief summary
This study is designed to assess the effect of fluvoxamine, itraconazole and smoking on the PK disposition of multiple doses TD-9855 in healthy male subjects. The study will also assess the relationship between caffeine PK and TD-9855 PK disposition in healthy male smokers and non-smokers.
Interventions
DRUGTD-9855
oral tablet, QD
DRUGFluvoxamine
oral tablet, QD
DRUGItraconazole
oral tablet solution, QD
DRUGCaffeine
oral solution, single dose
Sponsors
Theravance Biopharma
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
19 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Willing and able to give written, signed informed consent * Male subjects 19 to 55 years of age (inclusive) * Body mass index 19 to 32 kg/m2 (inclusive), and weigh at least 55 kg * No clinically important abnormal physical findings as determined by the Principal Investigator (PI) at the screening and Day -1 examinations * Negative for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) antibody at screening. * No clinically important laboratory abnormalities as determined by the PI * Ability to communicate effectively with the Investigator and to comply with all study requirements, restrictions, and direction of the clinic staff * Male subjects must abstain from sexual intercourse or use a highly effective method of birth control * Male smokers: Subjects who self-report to have smoked \> 9 cigarettes per day for at least 6 month prior to screening as confirmed by urine cotinine test at screening and Day -1. * Male smokers: Subjects must be willing to continue consistent use of their tobacco products throughout the study. * Additional inclusion criteria apply
Exclusion criteria
* Positive for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) antibody at screening. * History or presence of clinically significant respiratory, gastrointestinal, renal, hepatic, hematologic, neurologic (including history of seizure and insomnia), cardiovascular (including postural orthostatic hypotension or tachycardia), psychiatric (including depression and known addictive disorders), musculoskeletal, genitourinary (including urinary retention), immunologic, or dermatologic disorder. * Any other condition that, in the opinion of the PI, would confound or interfere with study participation; evaluation of safety, tolerability, or PK of the investigational drug; or prevent compliance with the study protocol * Any history of suicide attempts/ideation or current suicidal ideation. * Have participated in another clinical trial of an investigational drug (or medical device) within 30 days (or 5 half-lives of the investigational drug if longer than 30 days) prior to Screening, or are currently participating in another trial of an investigational drug (or medical device), or intending to participate in another trial of an investigational drug (or medical device) before completion of all scheduled safety evaluations in this trial * Additional inclusion criteria apply
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in TD-9855 plasma exposure when administered with itraconazole or fluvoxamine | Day 9 and Day 24 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation between caffeine PK disposition and TD-9855 plasma exposure | Day 9 and Day 24 | Correlation co-efficient will be calculated between caffeine/paraxanthine ratio at 4hr after caffeine dose and TD-9855 plasma AUC on Day 9 and Day 24. |
Countries
United States
Outcome results
None listed